 CASI Pharmaceuticals, Inc. Nasdaq: CASI, a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it submitted a Clinical Trial Application CTA IND with the United Kingdoms Medicines and Healthcare Products Regulatory Agency MHRA for CID-103, its novel anti-CD38 monoclonal antibody for the treatment of multiple myeloma and other hematological malignancies. 